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ABSTRACT: 
 Patients with chronic kidney disease (CKD) have increased risk of fractures, yet the 
optimal treatment is unknown.  In secondary analyses of large randomized trials, 
bisphosphonates have been shown to improve bone mineral density and reduce fractures.  
However, bisphosphonates are currently not recommended in patients with advanced kidney 
disease due to concern about over-suppressing bone remodeling, which may increase the risk of 
developing arterial calcification.  In the present study we used a naturally occurring rat model of 
CKD with secondary hyperparathyroidism, the Cy/+ rat, and compared the efficacy of treatment 
with zoledronic acid, calcium given in water to simulate a phosphate binder, and the combination 
of calcium and zoledronic acid.  Animals were treated beginning at 25 weeks of age 
(approximately 30% of normal renal function) and followed for ten weeks.  The results 
demonstrate that both zoledronic acid and calcium improved bone volume by microCT and both 
equally suppressed mineral apposition rate, bone formation rate, and mineralizing surface of 
trabecular bone.  In contrast, only calcium treatment with or without zoledronic acid improved 
cortical porosity and cortical biomechanical properties (ultimate load and stiffness) and lowered 
parathyroid hormone (PTH).  However, only calcium treatment led to the adverse effects of 
increased arterial calcification and fibroblast growth factor 23 (FGF23).  These results suggest 
zoledronic acid may improve trabecular bone volume in CKD in the presence of secondary 
hyperparathyroidism, but does not benefit extraskeletal calcification or cortical biomechanical 
properties. Calcium effectively reduces PTH and benefits both cortical and trabecular bone yet 
increases the degree of extra skeletal calcification.   
INTRODUCTION: 
Chronic kidney disease – mineral and bone disorder (CKD-MBD) is a disorder of 
abnormal biochemistries, bone fragility and arterial calcification in patients with advanced 
CKD(1).  Patients with CKD have increased risk of bone fracture compared to the general 
population(2).  The increased fracture risk is due to a combination of abnormal bone quantity and 
quality(3,4).   
The pathophysiology of bone loss associated with CKD-MBD is different than post- 
menopausal osteoporosis suggesting that extrapolation of data from trials of treatments in post-
menopausal or corticosteroid-induced osteoporosis may not be appropriate.  Secondary analyses 
of randomized controlled trials of bisphosphonates in post-menopausal women subsequently 
identified to have kidney disease demonstrated reduced fracture risk and improved bone mineral 
density without adverse consequences(5-7).  However, these patients had neither advanced 
kidney disease nor elevated PTH levels.    These differences provided the rationale for global 
clinical practice guidelines to recommend against treating patients with CKD stage 3b-5 with 
bisphosphonates without a bone biopsy(8).  We have previously used our slowly progressive 
animal model of CKD-MBD to test different doses of the bisphosphonate zoledronic acid on 
bone mass, turnover, and biomechanical properties in animals with hyperparathyroidism and 
moderate renal disease(9).  In the present study, we extend these findings to compare the skeletal 
(both cortical and cancellous) and vascular effects of zoledronic acid with and without calcium in 
the setting of high and low PTH levels in CKD animals with more advanced renal disease. 
 
MATERIALS AND METHODS: 
Animal model and experimental design: 
  Male Cy/+ rats, Han:SPRD rats with autosomal dominant polycystic kidney disease, and 
their non-affected (normal) littermates were used for this study.  Male heterozygous rats (Cy/+) 
develop characteristics of CKD (azotemia) around 10 weeks of age which progresses to terminal 
uremia by about 40 weeks.  This animal model spontaneously develops all three manifestations 
of CKD-MBD: biochemical abnormalities, extra skeletal calcification, and abnormal 
bone(10,11). 
At 25 weeks of age, animals were assigned to treatment groups.  In the CKD (Cy/+) 
animals, this age represents approximately 30-40% of the kidney function of the normal 
littermates.  This was chosen to simulate late stage 3 CKD, a stage at which there is elevated 
PTH, yet normal calcium and phosphorus levels, and a stage at which clinical practice guidelines 
do not recommend treatment with bisphosphonates(8). The CKD treatment groups (n=10 per 
group) were given 1) a single subcutaneous (SQ) dose of vehicle as control (CTL) and normal 
deionized drinking water,  2) a single SQ dose of zoledronic acid (ZOL) (20 µg/kg body weight) 
and normal deionized drinking water,  3) no injection but administered 3% calcium gluconate 
(3% Ca) in the drinking water, or 4) Zoledronic acid plus 3% Ca in the drinking water (Ca + 
ZOL).   The calcium gluconate group was used to simulate calcium administration as a 
phosphate binder.  In addition, we studied age-matched normal (NL) littermate animals (n = 10) 
to determine if treatments normalized bone manifestations or extra skeletal calcification.  All 
animals were fed a casein diet (Purina AIN-76A; 0.53% Ca and 0.56% P) during the experiment 
which has been shown to produce a more consistent kidney disease in this model(10).   Two 
weeks prior to the end of the study, all animals were given an intraperitoneal injection of calcein 
(1% concentration, 0.1mL/100g body weight); a second injection was given 10 days later.  At 35 
weeks of age all animals were euthanized by an overdose of sodium pentobarbital.   All 
procedures were reviewed and approved by the Indiana University School of Medicine 
Institutional Animal Care and Use Committee.   
Tissues collection and analysis:   
At sacrifice at 35 weeks, blood and urine were collected by cardiac and bladder puncture, 
respectively.  The heart and aorta arch were excised and weighed.  Left ventricular mass index 
(LVMI) was determined by dividing total heart weight by body weight.  To quantify aorta and 
heart calcification, proximal segments of the ascending aorta and a segment of the inferior apex 
of the left ventricle of the heart were snap frozen and the degree of calcification determined 
biochemically as previously described (12). Left tibiae were placed in 10% neutral buffered 
formalin for 48 hours and then changed to 70% ethanol for imaging followed by histological 
processing.  
Serum and urine biochemical measurements:   
Blood plasma was analyzed for BUN, calcium, phosphorus, and creatinine using 
colorimetric assays (Point Scientific, Canton, MI, USA, or Sigma kits).  Intact PTH was 
determined by ELISA (Alpco, Salem, NH, USA).  FGF23 was assessed with a two-site assay 
(Immunotopics, San Clemente, CA, USA).  Urine was analyzed for creatinine, calcium, and 
phosphorus using the colorimetric methods described above (11).   
Computed tomography (CT):   
Morphological parameters of the proximal tibia were assessed using high-resolution 
microCT (Skyscan 1172).  Bones were wrapped in parafilm to prevent drying during scanning. 
Scans were obtained using an x-ray source, set at 60kV and 167 µA over an angular range of 180 
degrees (rotational steps of 0.70 degrees) with a 12-µm pixel size. Projection images were 
reconstructed using standard Skyscan software (NRecon). A 1mm region of interest of the 
proximal tibia (located ~ 0.5 mm distal to the growth plate) was analyzed by segmenting the 
trabecular bone from the cortical shell and calculating trabecular bone volume per total volume 
(BV/TV) in accordance with recommended guidelines (13).   On the most distal slice of the 1 
mm region of interest, the cortical shell was manually isolated from the trabecular bone by 
tracing the periosteal and endocortical edges.  Porosity of the cortical shell was calculated as 
total bone area within the cortex divided by total area of bone plus void space within the cortex.  
Bone Histomorphometry:  
Tibiae were embedded in methylmethacrylate for sectioning as previously 
described(9,14). The proximal tibial metaphysis was thin sectioned (4 µm) and mounted 
unstained using non-fluorescent medium. Sections were analyzed using a microscope interfaced 
with a semiautomatic analysis system (Bioquant OSTEO 7.20.10, Bioquant Image Analysis Co.).  
Two of ten CKD vehicle-treated animals, and two of nine CKD calcium-treated animals did not 
have double labels in the proximal tibia section region of interest.  In these animals, tibia 
midshafts were sectioned and also found to contain no double label.  This suggests these animals 
were not properly administered both labels (likely due to injection directly into bladder) and thus 
these animals were excluded from the histological analysis, according to previously published 
recommendations(15).  For trabecular bone analyses, a region of interest of approximately 8 
mm
2
 within the secondary spongiosa (~ 0.5 mm distal to the growth plate) was defined, and then 
measures of single- and double-label perimeter (sL.Pm, dL.Pm), total bone perimeter (B.Pm) and 
interlabel width (Ir.L.Wi) were conducted. From these primary measurements, derived 
parameters were calculated as: mineralizing surface (MS/BS = [1/2sL.Pm + dL.Pm]/B.Pm; %), 
mineral apposition rate (MAR =Ir.l.W/days between labels; μm/day), and bone formation rate 
(BFR/BS = MAR x MS/BS x 3.65; μm3/μm2/yr). All parameters were measured and calculated 
in accordance with ASBMR recommended standards(16).   
Bone Mechanics:  
Femora were tested via three-point bending using standard methods as previously described for 
the rat.(9).  Femora were thawed to room temperature, hydrated in 0.9% saline, and placed on the 
bottom support of a servo-hydraulic
 
test system (Test Resources). All bones were loaded to 
failure in an anterior-posterior direction using a displacement rate of 2 mm/min with force vs. 
displacement data collected at 10 Hz. Structural mechanical properties, ultimate load, stiffness, 
and energy to failure were determined from the load-deformation curves using standard 
definitions.  
 
Statistics:   
All analyses were run using SigmaStat software.  The five groups were compared using a one-
way ANOVA with Fisher’s post-hoc analyses for within group comparisons.    Correlations were 
examined by the Pearson product-moment algorithm.  A priori α-levels were set at 0.05.  Data 
are presented as means and standard errors. 
 
RESULTS: 
 Biochemical outcomes:  At 35 weeks, there was no difference in the plasma BUN in the 
CKD animal treatment groups, but values for all CKD animals were higher than normal animals 
as expected  (CKD BUN 59.6 ± 1.5 vs. NL BUN 19.9 ± 0.63 mg/dl).  The total body weight was 
not different between any of the 5 groups.  There were overall differences in the other blood 
results (Figure 1 A-D):  In the CKD rats, treatment with calcium, both alone and in combination 
with zoledronic acid, led to an increase in plasma calcium (p < 0.001) and FGF23 (p < 0.005) 
levels and a decrease in PTH (p < 0.001) and phosphorus (p < 0.05) levels compared to CKD-
CTL.  In contrast, treatment with zoledronic acid alone had no significant effect on these 
biochemical measures.  The effect of the combination of zoledronic acid with calcium was not 
different than calcium alone for any of these plasma biochemistry results.   The plasma calcium 
level was negatively correlated with PTH (r = -0.53, p < 0.001) and positively correlated with 
FGF23 (r = 0.44, p < 0.002).  The plasma phosphorus level was more strongly related to the PTH 
(r = 0.79, p < 0.001) than FGF23 (r = 0.33, p < 0.003).  The urine calcium/creatinine ratio was 
significantly increased in both calcium treatment groups (Vehicle = 0.27 ± 0.09; Zol = 0.27 ± 
0.12; Ca = 0.70 ± 0.22; Zol + Ca = 0.50 ± 0.20 mg/mg, p < 0.0001).  The urine 
phosphorus/creatinine ratio was decreased in both calcium treatment groups (Vehicle = 1.33 ± 
0.56; Zol = 1.75 ± 0.44; Ca = 1.08 ± 0.49; Ca + Zol = 0.79 ± 0.35 mg/mg, overall p = 0.002).  
The albumin/creatinine ratio was not different among the groups.   
Cardiovascular outcomes:  At 35 weeks, the CKD animals had increased left ventricular 
mass index (LVMI) compared to normal animals (p<0.001) that was unaffected by treatments 
(CKD + CTL = 3.8 ± 0.19, CKD + Ca = 3.9 ± 1.2, CKD + ZOL = 4.0 ± 0.4, CKD + Ca + ZOL = 
4.0 ± 0.4, Nl +Vehicle 3.2 ± 0.06, overall p = 0.035).  However, treatment with calcium 
increased aortic arch calcium content, and this adverse effect was mitigated by zoledronic acid 
(Figure 2).     The aorta arch calcium content was significantly (all p < 0.01) correlated with 
LVMI (r = 0.48), BUN (r = 0.47), calcium (r = 0.43), and FGF23 (r = 0.51)  but not phosphorus 
or PTH.    In contrast to our previous studies in this model (12), there was no difference in the 
heart calcification between any of the groups.    
Bone outcomes:  By microCT, there was no difference in the trabecular bone volume 
between CKD and NL animals.   ZOL, calcium, and calcium + ZOL treatment significantly 
increased percent bone volume (p<0.0001) in CKD rats but there was no difference among these 
three treatment groups (Figure 3A).  The bone volume was strongly correlated with trabecular 
number (r = 0.77, p < 0.001).   The trabecular bone volume was positively correlated with the 
calcium (r = 0.53) and FGF23 (r = 0.42), negatively correlated with PTH (r = -0.47; all p < 0.01), 
but not correlated with phosphorus.     Cortical porosity was increased in CKD animals compared 
to normal animals, with significant reduction in animals treated with calcium and calcium plus 
ZOL; the ZOL treatment showed a non-significant reduction (p = 0.13;Figure 3B).   
Corresponding three-dimensional reconstruction of the microCT images are shown in Figure 3C.   
The magnitude of cortical porosity was strongly associated with phosphorus (r = 0.80) and PTH 
(r = 0.70, both p < 0.001), but not associated with FGF23, calcium or bone volume.   
Dynamic bone histomorphometry demonstrated that the mineralization apposition rate 
(MAR) was increased in the CKD animals compared to normal, and decreased by all treatments 
in the CKD animals to levels similar to that observed in NL animals (Figure 4A).   Similar 
results were observed for mineralizing surface (MS/BS; Figure 4B) and BFR (Figure 4C).   PTH 
and phosphorus were positively associated with all three histomorphometric indices with the 
strongest relationship with MAR (r = 0.61 for PTH and r = 0.42 for phosphorus, both p < 0.01).    
The calcium level was negatively correlated only with BFR (r = -0.35, p = 0.03) and MS/BS (r =-
0.53, p < 0.001).  
Ultimate load and stiffness of the femoral diaphysis were both significantly lower in 
untreated CKD animals compared to NL (Table 1, Figure 5).   CKD animals treated with ZOL 
had properties similar to untreated CKD (and lower than NL-VEH), while those treated with 
calcium, or the combination of ZOL and calcium had mechanical properties significantly higher 
than CKD and similar to NL. 
Relationship of bone to cardiovascular outcomes:  The aortic arch calcification was 
correlated with trabecular bone volume (r= 0.43, p = 0.005) and cortical porosity (r = 0.34, p = 
0.03), but not with any of the three histormorphometry measures.   
DISCUSSION: 
Multiple studies have documented increased fractures in patients with CKD due to a 
combination of abnormal bone volume and bone quality(17,18).   While secondary analyses 
support the use of bisphosphonates in post-menopausal women with moderate to advanced 
kidney disease, these studies did not enroll individuals with elevated PTH levels (5,7).   Clinical 
practice guidelines recommend lowering PTH as a primary treatment approach in CKD(8).  
There is no evidence that bisphosphonates directly reduce PTH; however their potent bone 
resorption inhibition could effectively offset the osteoclast-medicated effects of high PTH.   We 
have previously shown efficacy of zoledronic acid in improving trabecular bone volume in 
animals with earlier stages of CKD and mild hyperparathyroidism(9).  In the present study we 
tested the hypothesis that zoledronic acid would be efficacious in animals with more advanced 
CKD, severe hyperparathyroidism, and even when combined with oral calcium supplementation.  
The latter has been shown to induce low bone turnover in patients on dialysis(19).  Our results 
demonstrate that individually, zoledronic acid and calcium each improved trabecular bone 
volume and reduced bone formation rate and the mineralizing surface to a similar magnitude, but 
only the calcium treatment improved cortical porosity and cortical biomechanical properties.  In 
addition, only the calcium treatment induced hypercalcemia and increased arterial calcification, 
although hypercalcemia was not a prerequisite for aortic calcification.  These results demonstrate 
that lowering PTH is more effective at improving cortical bone porosity and biomechanical 
integrity; however, doing so with calcium may adversely impact arterial calcification risk.  The 
elevations in plasma calcium levels may have a played a role in inducing aorta calcification, and 
it is possible that lower doses of calcium would not results in this adverse effect.  In our previous 
study in this animal model we demonstrated that the administration of calcium at similar doses to 
the current study led to aorta calcification.  This occurred even if the calcium was given  together 
with a calcimimetic that resulting in normal plasma calcium levels resulting in increased calcium 
load but normal calcium levels(12).  These results would imply that it is the calcium load, not the 
level itself that contributes to calcification.  However, dose finding studies would be required to 
fully assess the importance of elevated calcium levels versus calcium load or decreased bone 
formation.     
The concern over the use of bisphosphonates in CKD has been the potential induction of 
low turnover bone disease(8).  In the present study, zoledronic acid did not suppress BFR any 
more than calcium alone.    In humans, zoledronic acid has been shown to improve bone mineral 
density and reduce bone fractures in both primary and secondary prevention trials in patients 
with post-menopausal osteoporosis(20-22).  In contrast, in post-menopausal osteoporosis the 
efficacy of calcium alone on fracture prevention is minimal to uncertain(23) and its adverse 
effects have recently come under scrutiny(24).  We cannot definitively determine if the efficacy 
of calcium on bone in the present study was due to calcium itself, or suppression of PTH, but 
based on the strong correlation of PTH, but not calcium, with cortical porosity  it is most likely 
PTH-mediated.  Interestingly, the effects of zoledronic acid on improving trabecular bone 
volume in the present study was less than compared to our previous study(9) when the drug was 
given at an earlier time point with less severe hyperparathyroidism and over a 5 week duration.  
One possible explanation is that the severe hyperparathyroidism induced such a profound 
increase in bone resorption that the zoledronic acid bound to bone was actually resorbed out of 
bone with the ‘first pass’ effect of the osteoclasts, leaving little drug bound for continued effect 
as the drug was only dosed one time.  This dosing schedule was used to mimic the dosing to 
osteoporosis patients, where a single dose is given once per year – about two remodeling cycles 
in humans.  Ten weeks in a rat is also equivalent to about two remodeling cycles.   If true that a 
single dose was inefficient to control osteoclasts over this duration, this could be overcome by 
using a less potent bisphosphonate, such as alendronate or risedronate, normally administered on 
a more regular basis (daily/weekly). Current clinical practice guidelines recommend dose 
reduction of bisphosphonates in the setting of CKD(8).  Our data suggests that the 
pharmacokinetics could be altered in the setting of significant secondary hyperparathyroidism 
requiring increased dosing frequency although perhaps a lower dose could still be given.    Thus, 
further studies are needed to evaluate pharmacokinetics of bisphosphonates in CKD, and further 
studies should determine if the efficacy and adverse effects of zoledronic acid are different when 
given to CKD animals and humans with and without hyperparathyroidism.    It should also be 
emphasized that changes in bone volume may not reflect an improvement in biomechanical 
properties/strength.  Zoledronic acid did not improve cortical measures of strength, but similar 
measures to test strength of trabecular bone are not available. 
In our CKD animals, the hyperparathyroidism produced profound changes in cortical 
bone porosity and biomechanical properties that were corrected with the administration of 
calcium.  Cortical bone is more adversely affected than trabecular bone in 
hyperparathyroidism(25,26).  However, traditional assessment of renal osteodystrophy by bone 
biopsy in CKD patients has been with trabecular bone.  Our results suggest that the apparent 
disconnect between PTH and bone turnover assessed by histology in cross sectional studies(27)  
may be partly due to the use of trabecular bone.  Supporting this is that in patients with CKD, the 
distal radius X-ray absorptiometry (DXA), which is nearly entirely cortical bone, is more 
predictive of fractures than other sites(28).   These data, and our results in the present study, 
support current clinical practice guidelines that emphasize treating hyperparathyroidism as first 
line agent in patients with CKD stages 3-5D(8).    However, in a recent study of nearly 4000 
hemodialysis patients, the largest fracture assessment study to date in CKD, there was no effect 
of the calcimimetic cinacalcet on fractures despite improved PTH(29).  However, this study only 
evaluated clinical (reported) fractures and thus may have underestimated true fracture prevalence 
and efficacy of lowering PTH.  Thus more studies specifically designed to compare the treatment 
of hyperparathyroidism versus anti-resorptive agents on fracture prevention in CKD are required.   
Previous studies have demonstrated that bisphosphonates reduce arterial calcification in 
CKD animal models.   Tamura found that etidronate decreased arterial calcification in 5/6
th
 
nephrectomy rats also given calcitriol(30).   Price found similar efficacy in the adenine model of 
CKD treated with alendronate or ibandronate (31).  Lomashevilli found that pamidronate 
reduced arterial calcification in 5/6
th
 nephrectomy animals treated with high phosphate diet, but 
also found suppression of bone turnover and concluded the drug may be efficacious but not safe, 
although there was no comparison of the degree of bone turnover to normal animals (32).  
Bisphosphonates work by suppression of remodeling and therefore induce lower bone formation 
rates are expected.  In our previous study, the level of BFR suppression was no different in CKD 
animals treated with zoledronic acid compared to normal animals treated with zoledronic acid(9).  
In the current study, the turnover was equally suppressed with zoledronic acid compared to 
calcium given in the drinking water (to act as a phosphate binder, a treatment used worldwide). 
A major concern about inducing suppressed bone turnover is the association of  such 
suppression with arterial calcification in patients with CKD and in dialysis patients(19,33,34).  
This has been hypothesized to be due to the inability of bone to take up excess calcium in the 
setting of low bone formation rates(35), predisposing to extra skeletal deposition.  In the present 
study we found that despite similar suppression of BFR with zoledronic acid and calcium, only 
the calcium induced arterial calcification and suppression of PTH and zoledronic acid appears to 
ameliorate this effect but had no efficacy by itself.   Thus, positive calcium balance which occurs 
in CKD(36) may be a critical factor involved in the development of arterial calcification.  The 
calcium treatment also increased FGF23 as has been previously noted in animals(37).  In other 
studies of human and animal arteries, FGF23 appeared to be protective against arterial 
calcification, but only when klotho was present(38).  We have previously shown in our animal 
model that klotho expression in the kidney is markedly decrease as early as 20 weeks(11) and 
thus, assuming similar suppression in arteries, this potential positive effect of FGF23 may have 
been negated with advanced kidney disease.  The mechanism by which calcium stimulates 
FGF23 is likely direct on the osteocytes, as calcium altered FGF23 secretion in rats who had 
undergone a parathyroidectomy and then were infused with calcium or given a high calcium diet 
(37).   This increase in FGF23 may have adverse cardiac consequences in rodents(33,39), and 
higher FGF23 levels have been found to predict progression of LVH in patients with CKD 3-
4(39).   In the current study, we did not observe differences in the LVH in animals with the 
various treatments, but the duration of therapy was relatively short.     
In humans with ESRD, there are only small studies examining the role of 
bisphosphonates in the prevention of arterial calcification.  In small cohort or observational 
studies from Japan, etidronate reduced arterial calcification(40-42).  In contrast, in a randomized 
controlled trial of 50 patients, Toussaint et al found that alendronate had no effect on arterial 
calcification(43).  These differences may be explained by the increased mineral dissolution 
properties of etridronate compared to alendronate and other nitrogen containing bisphosphonates, 
although a number of other explanations such as dosing and disease stage are also plausible.   
In summary, we found similar efficacy of calcium and a single dose of zoledronic acid on 
improving trabecular bone volume in animals with advanced CKD and severe 
hyperparathyroidism.  However, only the calcium treatment improved cortical porosity and 
lowered PTH.  Unfortunately, calcium also induced arterial calcification whereas zoledronic acid 
did not despite similar suppression of bone remodeling.  These results suggest that suppression 
of bone remodeling with bisphosphonates may not have the same adverse consequences as 
suppression of bone remodeling with calcium.   It is important to caution on the extrapolation of 
changes in bone remodeling or bone volume in animal studies to human disease.  However, the 
data supports the conduct of a study in CKD patients directly testing whether suppression of 
PTH with non-calcium containing agents (e.g. calcimimetics) are more effective than anti-
resorptive agents for fracture prevention.     
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TABLE 1:  Biomechanical properties of femoral diaphysis 
 CKD-CTL 
(n=10) 
CKD-Ca 
(n=9) 
CKD-ZOL 
(n=9) 
CKD-Ca + 
ZOL(n=6) 
NL 
Ultimate 
Load, N 
142 + 31 * 222 + 11 +# 160 + 42 * 219 + 18 +# (n=10) 
Stiffness, 
N/mm 
395 + 55 * 512 + 20 +# 378 + 90 * 473 + 32 +# 206 + 20 
Energy to 
Failure, mJ 
72 + 31 83 + 12 80 + 37 85 + 18 473 + 32 
Data presented as mean ± SD.  p < 0.05 vs NL (*) ,CKD-CTL (+) and CKD-ZOL (#). 
 
 
  
FIGURE LEGENDS: 
Figure 1:  Biochemical changes in response to therapies:  CKD animals were treated 
beginning at 25 weeks of age with control vehicle (CTL), calcium in drinking water daily for 10 
weeks (Ca), zoledronic acid 20 ug/kg given subcutaneously once at 25 weeks (ZOL), or the 
combination of Ca + ZOL.  The results were compared to normal animals (NL) treated with 
vehicle.  Blood was drawn at 35 weeks of age. The results demonstrate that treatment with 
calcium, with or without zoledronic acid, led to increased calcium levels (A), increased fibroblast 
growth factor 23 (B),  decreased parathyroid hormone levels to those in normal animals (C), and 
decreased phosphorus levels (D).  *= different than NL; + = different than CKD-CTL; # = 
different than CKD + ZOL; all p < 0.05.  Graphs are mean ± SEM, n = 8 to 10 per group. 
Figure 2:  Aorta arch calcification in response to therapies:  CKD animals were treated 
beginning at 25 weeks of age with control vehicle (CTL), calcium in drinking water daily for 10 
weeks (Ca), zoledronic acid 20 ug/kg given subcutaneously once at 25 weeks (ZOL), or the 
combination of Ca + ZOL.  The results were compared to normal animals (NL) treated with 
vehicle.   The aorta calcium content was determined biochemically.  The results demonstrated 
that CKD animals given any treatment had increased aorta calcification compared to NL animals, 
and that the treatment with calcium increased calcification further among the CKD animals.  The 
co-administration of calcium with zoledronic acid led to a reduction of the calcium induced 
arterial calcification compared to calcium alone.  *= different than NL; + = different than CKD-
CTL; $ = different than CKD + Ca; all p < 0.05.  Graphs are mean ± SEM, n = 8 to 10 per group. 
Figure 3: Trabecular bone volume and cortical porosity in response to therapies:  CKD 
animals were treated beginning at 25 weeks of age with control vehicle (CTL), calcium in 
drinking water daily for 10 weeks (Ca), zoledronic acid 20 ug/kg given subcutaneously once at 
25 weeks (ZOL), or the combination of Ca + ZOL.  The results were compared to normal 
animals (NL) treated with vehicle.  At sacrifice at 35 weeks, the tibiae were assessed by microCT 
for trabecular bone volume (A) and cortical porosity (B).  The results demonstrate that there was 
no difference in trabecular bone volume between CKD and NL animals treated with vehicle.  
However, all of the treatments led to higher bone volume in the CKD animals compared to 
CKD-vehicle.  In contrast, the cortical porosity was increased in vehicle treated CKD animals 
compared to NL animals.  Treatment with calcium, or calcium plus zoledronic acid, but not ZOL 
alone, reduced cortical porosity to NL levels.  The 3D reconstructions (C) provide visualization 
of these trabecular and cortical effects across groups.*= different than NL; + = different than 
CKD-CTL; all p < 0.05.  Graphs are mean ± SEM, n = 7 to 10 per group.   
Figure 4: Bone histomorphometry in response to therapies:  CKD animals were treated 
beginning at 25 weeks of age with control vehicle (CTL), calcium in drinking water daily for 10 
weeks (Ca), zoledronic acid 20 ug/kg given subcutaneously once at 25 weeks (ZOL), or the 
combination of Ca + ZOL.  The results were compared to normal animals (NL) treated with 
vehicle.  At sacrifice at 35 weeks, the tibiae were processed for bone histomorphometry.  The 
results for mineral apposition rate (MAR; A), mineralizing surface as a percentage of bone 
surface (MS/BS; B), and bone formation rate (BFR; C).  The results demonstrate that there was 
higher MAR, BFR, and MS/BS in the CKD animals treated with vehicle compared to NL 
animals.  Treatment with calcium or zoledronic acid reduced all parameters to levels similar in 
the NL animals with additive reduction in the calcium plus zoledronic acid group.  The   *= 
different than NL; + = different than CKD-CTL; # = different than CKD + ZOL; all p < 0.05.  
Graphs are mean ± SEM, n = 7 to 10 per group.   
Figure 5: Bone biomechanics in response to therapies:  CKD animals were treated beginning 
at 25 weeks of age with control vehicle (CTL), calcium in drinking water daily for 10 weeks 
(Ca), zoledronic acid 20 ug/kg given subcutaneously once at 25 weeks (ZOL), or the 
combination of Ca + ZOL.  The results were compared to normal animals (NL) treated with 
vehicle.  At sacrifice at 35 weeks, the femora were tested via three-point bending.  The results 
demonstrate that the CKD animals had reduced ultimate load (fracture predisposition) than 
normal animals and this was improved by calcium treatment with or without zoledronic acid  
The   *= different than NL; + = different than CKD-CTL; # = different than CKD + ZOL; all p < 
0.05.  Graphs are mean ± SEM, n = 7 to 10 per group.   
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